10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ORY (Oryzon) Stock Analysis
Buy, Hold or Sell?

Let's analyze Oryzon together

I guess you are interested in Oryzon Genomics SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Oryzon’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Oryzon’s Price Targets

I'm going to help you getting a better view of Oryzon Genomics SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Oryzon Genomics SA

I send you an email if I find something interesting about Oryzon Genomics SA.

1. Quick Overview

1.1. Quick analysis of Oryzon (30 sec.)










1.2. What can you expect buying and holding a share of Oryzon? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€1.12
Expected worth in 1 year
€1.39
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
€0.27
Return On Investment
10.1%

For what price can you sell your share?

Current Price per Share
€2.69
Expected price per share
€2.51 - €2.96
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Oryzon (5 min.)




Live pricePrice per Share (EOD)
€2.69
Intrinsic Value Per Share
€-0.51 - €0.52
Total Value Per Share
€0.61 - €1.64

2.2. Growth of Oryzon (5 min.)




Is Oryzon growing?

Current yearPrevious yearGrowGrow %
How rich?$102.1m$96m$6.1m6.1%

How much money is Oryzon making?

Current yearPrevious yearGrowGrow %
Making money-$4.3m-$3.9m-$366.3k-8.5%
Net Profit Margin-49.8%-23.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Oryzon (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#337 / 874

Most Revenue
#305 / 874

Most Profit
#390 / 874

Most Efficient
#476 / 874
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Oryzon?

Welcome investor! Oryzon's management wants to use your money to grow the business. In return you get a share of Oryzon.

First you should know what it really means to hold a share of Oryzon. And how you can make/lose money.

Speculation

The Price per Share of Oryzon is €2.69. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Oryzon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Oryzon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €1.12. Based on the TTM, the Book Value Change Per Share is €0.07 per quarter. Based on the YOY, the Book Value Change Per Share is €0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Oryzon.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps-0.06-2.1%-0.06-2.1%-0.05-1.9%-0.06-2.1%-0.06-2.2%-0.05-2.0%
Usd Book Value Change Per Share0.083.0%0.083.0%0.145.2%0.083.0%0.020.8%0.114.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.083.0%0.083.0%0.145.2%0.083.0%0.020.8%0.114.1%
Usd Price Per Share1.64-1.64-2.22-2.26-2.81-3.23-
Price to Earnings Ratio-29.61--29.61--43.65--39.56--48.63--82.64-
Price-to-Total Gains Ratio20.60-20.60-15.90-61.08-14.40-6.22-
Price to Book Ratio1.25-1.25-1.79-1.90-2.44-4.94-
Price-to-Total Gains Ratio20.60-20.60-15.90-61.08-14.40-6.22-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.158329
Number of shares316
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.080.02
Usd Total Gains Per Share0.080.02
Gains per Quarter (316 shares)25.216.73
Gains per Year (316 shares)100.8626.91
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101019102717
2020219205444
3030329308171
40403394010898
505044950135125
606055960161152
707066970188179
808077980215206
909088990242233
100100910000269260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%1.011.00.08.3%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%3.02.00.060.0%7.03.00.070.0%8.04.00.066.7%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.012.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%3.02.00.060.0%7.03.00.070.0%8.04.00.066.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Oryzon Genomics SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0680.0680%0.119-43%0.068+0%0.018+275%0.094-28%
Book Value Per Share--1.1231.1230%1.055+6%1.038+8%1.003+12%0.772+45%
Current Ratio--0.7450.7450%0.870-14%0.986-24%2.445-70%2.961-75%
Debt To Asset Ratio--0.1990.1990%0.235-15%0.245-19%0.236-16%0.281-29%
Debt To Equity Ratio--0.2490.2490%0.307-19%0.328-24%0.313-20%0.450-45%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--92462744.00092462744.0000%133475960.000-31%136120023.000-32%182994390.600-49%202809271.400-54%
Eps---0.047-0.0470%-0.043-9%-0.048+2%-0.050+6%-0.046-2%
Ev To Ebitda Ratio---20.853-20.8530%-31.318+50%-29.370+41%-37.913+82%1.982-1152%
Ev To Sales Ratio--12.56512.5650%9.405+34%11.197+12%16.897-26%1111.488-99%
Free Cash Flow Per Share---0.073-0.0730%-0.195+165%-0.159+116%-0.171+133%-0.156+112%
Free Cash Flow To Equity Per Share--0.0150.0150%-0.117+866%-0.066+531%-0.057+476%-0.023+251%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.262-21%
Intrinsic Value_10Y_max--0.517----------
Intrinsic Value_10Y_min---0.513----------
Intrinsic Value_1Y_max---0.114----------
Intrinsic Value_1Y_min---0.142----------
Intrinsic Value_3Y_max---0.215----------
Intrinsic Value_3Y_min---0.351----------
Intrinsic Value_5Y_max---0.165----------
Intrinsic Value_5Y_min---0.475----------
Market Cap208509970.000+48%108518200.000108518200.0000%146344544.000-26%149031661.333-27%185535116.800-42%212982470.100-49%
Net Profit Margin---0.498-0.4980%-0.236-53%-0.335-33%-0.360-28%-31.999+6325%
Operating Margin---0.623-0.6230%-0.311-50%-0.423-32%-0.476-24%-27.408+4302%
Operating Ratio--1.6011.6010%1.321+21%1.090+47%1.076+49%27.411-94%
Pb Ratio2.395+48%1.2471.2470%1.790-30%1.895-34%2.439-49%4.944-75%
Pe Ratio-56.892-92%-29.609-29.6090%-43.646+47%-39.562+34%-48.628+64%-82.640+179%
Price Per Share2.690+48%1.4001.4000%1.888-26%1.923-27%2.394-42%2.748-49%
Price To Free Cash Flow Ratio-36.647-92%-19.073-19.0730%-9.706-49%-13.568-29%-14.726-23%-13.354-30%
Price To Total Gains Ratio39.582+48%20.60020.6000%15.903+30%61.079-66%14.398+43%6.224+231%
Quick Ratio--0.5410.5410%0.830-35%0.850-36%2.353-77%4.467-88%
Return On Assets---0.034-0.0340%-0.031-7%-0.035+5%-0.038+13%-0.047+40%
Return On Equity---0.042-0.0420%-0.041-3%-0.047+12%-0.050+20%-0.076+82%
Total Gains Per Share--0.0680.0680%0.119-43%0.068+0%0.018+275%0.094-28%
Usd Book Value--102196521.759102196521.7590%96011601.302+6%94471675.615+8%91246823.596+12%70267094.869+45%
Usd Book Value Change Per Share--0.0800.0800%0.139-43%0.080+0%0.021+275%0.111-28%
Usd Book Value Per Share--1.3181.3180%1.239+6%1.219+8%1.177+12%0.907+45%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--108560507.730108560507.7300%156714124.636-31%159818519.004-32%214853714.003-49%238118365.551-54%
Usd Eps---0.056-0.0560%-0.051-9%-0.057+2%-0.059+6%-0.054-2%
Usd Free Cash Flow---6680265.029-6680265.0290%-17702564.370+165%-14435757.532+116%-15571733.722+133%-11350215.139+70%
Usd Free Cash Flow Per Share---0.086-0.0860%-0.228+165%-0.186+116%-0.201+133%-0.183+112%
Usd Free Cash Flow To Equity Per Share--0.0180.0180%-0.137+866%-0.077+531%-0.067+476%-0.027+251%
Usd Market Cap244811555.777+48%127411218.620127411218.6200%171823129.110-26%174978073.571-27%217836780.635-42%250062718.144-49%
Usd Price Per Share3.158+48%1.6441.6440%2.217-26%2.257-27%2.810-42%3.226-49%
Usd Profit---4303076.500-4303076.5000%-3936757.300-9%-4402483.633+2%-4540479.520+6%-4207364.807-2%
Usd Revenue--8640201.9008640201.9000%16662827.200-48%14578016.967-41%13475145.700-36%9328190.569-7%
Usd Total Gains Per Share--0.0800.0800%0.139-43%0.080+0%0.021+275%0.111-28%
 EOD+6 -2MRQTTM+0 -0YOY+16 -213Y+24 -135Y+24 -1310Y+19 -19

3.3 Fundamental Score

Let's check the fundamental score of Oryzon Genomics SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-56.892
Price to Book Ratio (EOD)Between0-12.395
Net Profit Margin (MRQ)Greater than0-0.498
Operating Margin (MRQ)Greater than0-0.623
Quick Ratio (MRQ)Greater than10.541
Current Ratio (MRQ)Greater than10.745
Debt to Asset Ratio (MRQ)Less than10.199
Debt to Equity Ratio (MRQ)Less than10.249
Return on Equity (MRQ)Greater than0.15-0.042
Return on Assets (MRQ)Greater than0.05-0.034
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Oryzon Genomics SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.061
Ma 20Greater thanMa 502.745
Ma 50Greater thanMa 1002.727
Ma 100Greater thanMa 2002.766
OpenGreater thanClose2.685
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Oryzon Genomics SA

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in CornellΓ  de Llobregat, Spain.

Fundamental data was last updated by Penke on 2025-07-02 00:46:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Oryzon earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Oryzon to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -49.8%Β means thatΒ €-0.50 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Oryzon Genomics SA:

  • The MRQ is -49.8%. The company is making a huge loss. -2
  • The TTM is -49.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-49.8%TTM-49.8%0.0%
TTM-49.8%YOY-23.6%-26.2%
TTM-49.8%5Y-36.0%-13.8%
5Y-36.0%10Y-3,199.9%+3,163.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-49.8%-92.7%+42.9%
TTM-49.8%-140.3%+90.5%
YOY-23.6%-196.4%+172.8%
3Y-33.5%-248.5%+215.0%
5Y-36.0%-343.4%+307.4%
10Y-3,199.9%-496.2%-2,703.7%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Oryzon is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Oryzon to theΒ Biotechnology industry mean.
  • -3.4% Return on Assets means thatΒ Oryzon generatedΒ €-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Oryzon Genomics SA:

  • The MRQ is -3.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.4%TTM-3.4%0.0%
TTM-3.4%YOY-3.1%-0.2%
TTM-3.4%5Y-3.8%+0.5%
5Y-3.8%10Y-4.7%+0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.4%-11.6%+8.2%
TTM-3.4%-11.6%+8.2%
YOY-3.1%-11.4%+8.3%
3Y-3.5%-11.8%+8.3%
5Y-3.8%-12.0%+8.2%
10Y-4.7%-13.7%+9.0%
4.3.1.3. Return on Equity

Shows how efficient Oryzon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Oryzon to theΒ Biotechnology industry mean.
  • -4.2% Return on Equity means Oryzon generated €-0.04Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Oryzon Genomics SA:

  • The MRQ is -4.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.2%TTM-4.2%0.0%
TTM-4.2%YOY-4.1%-0.1%
TTM-4.2%5Y-5.0%+0.8%
5Y-5.0%10Y-7.6%+2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.2%-13.6%+9.4%
TTM-4.2%-15.0%+10.8%
YOY-4.1%-14.5%+10.4%
3Y-4.7%-16.9%+12.2%
5Y-5.0%-17.5%+12.5%
10Y-7.6%-19.9%+12.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Oryzon Genomics SA.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Oryzon is operatingΒ .

  • Measures how much profit Oryzon makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Oryzon to theΒ Biotechnology industry mean.
  • An Operating Margin of -62.3%Β means the company generated €-0.62 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Oryzon Genomics SA:

  • The MRQ is -62.3%. The company is operating very inefficient. -2
  • The TTM is -62.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-62.3%TTM-62.3%0.0%
TTM-62.3%YOY-31.1%-31.2%
TTM-62.3%5Y-47.6%-14.7%
5Y-47.6%10Y-2,740.8%+2,693.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-62.3%-229.2%+166.9%
TTM-62.3%-249.0%+186.7%
YOY-31.1%-208.5%+177.4%
3Y-42.3%-223.8%+181.5%
5Y-47.6%-346.1%+298.5%
10Y-2,740.8%-475.5%-2,265.3%
4.3.2.2. Operating Ratio

Measures how efficient Oryzon is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 1.60 means that the operating costs are €1.60 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Oryzon Genomics SA:

  • The MRQ is 1.601. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.601. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.601TTM1.6010.000
TTM1.601YOY1.321+0.281
TTM1.6015Y1.076+0.525
5Y1.07610Y27.411-26.334
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6012.110-0.509
TTM1.6012.684-1.083
YOY1.3213.096-1.775
3Y1.0903.652-2.562
5Y1.0764.745-3.669
10Y27.4116.614+20.797
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Oryzon Genomics SA.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Oryzon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.75Β means the company has €0.75 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Oryzon Genomics SA:

  • The MRQ is 0.745. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.745. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.745TTM0.7450.000
TTM0.745YOY0.870-0.125
TTM0.7455Y2.445-1.700
5Y2.44510Y2.961-0.516
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7453.661-2.916
TTM0.7453.846-3.101
YOY0.8704.140-3.270
3Y0.9864.688-3.702
5Y2.4455.746-3.301
10Y2.9616.147-3.186
4.4.3.2. Quick Ratio

Measures if Oryzon is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Oryzon to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.54Β means the company can pay off €0.54 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Oryzon Genomics SA:

  • The MRQ is 0.541. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.541. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.541TTM0.5410.000
TTM0.541YOY0.830-0.289
TTM0.5415Y2.353-1.812
5Y2.35310Y4.467-2.114
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5412.826-2.285
TTM0.5413.182-2.641
YOY0.8303.786-2.956
3Y0.8504.311-3.461
5Y2.3535.703-3.350
10Y4.4676.454-1.987
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Oryzon Genomics SA.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of OryzonΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Oryzon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.20Β means that Oryzon assets areΒ financed with 19.9% credit (debt) and the remaining percentage (100% - 19.9%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Oryzon Genomics SA:

  • The MRQ is 0.199. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.199. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.199TTM0.1990.000
TTM0.199YOY0.235-0.036
TTM0.1995Y0.236-0.037
5Y0.23610Y0.281-0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1990.329-0.130
TTM0.1990.349-0.150
YOY0.2350.331-0.096
3Y0.2450.340-0.095
5Y0.2360.349-0.113
10Y0.2810.379-0.098
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Oryzon is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Oryzon to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 24.9% means that company has €0.25 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Oryzon Genomics SA:

  • The MRQ is 0.249. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.249. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.249TTM0.2490.000
TTM0.249YOY0.307-0.058
TTM0.2495Y0.313-0.064
5Y0.31310Y0.450-0.137
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2490.379-0.130
TTM0.2490.437-0.188
YOY0.3070.414-0.107
3Y0.3280.450-0.122
5Y0.3130.464-0.151
10Y0.4500.515-0.065
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Oryzon generates.

  • Above 15 is considered overpriced butΒ always compareΒ Oryzon to theΒ Biotechnology industry mean.
  • A PE ratio of -29.61 means the investor is paying €-29.61Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Oryzon Genomics SA:

  • The EOD is -56.892. Based on the earnings, the company is expensive. -2
  • The MRQ is -29.609. Based on the earnings, the company is expensive. -2
  • The TTM is -29.609. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-56.892MRQ-29.609-27.283
MRQ-29.609TTM-29.6090.000
TTM-29.609YOY-43.646+14.037
TTM-29.6095Y-48.628+19.019
5Y-48.62810Y-82.640+34.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-56.892-2.320-54.572
MRQ-29.609-2.085-27.524
TTM-29.609-2.564-27.045
YOY-43.646-3.764-39.882
3Y-39.562-3.773-35.789
5Y-48.628-6.167-42.461
10Y-82.640-6.833-75.807
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Oryzon Genomics SA:

  • The EOD is -36.647. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -19.073. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -19.073. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-36.647MRQ-19.073-17.574
MRQ-19.073TTM-19.0730.000
TTM-19.073YOY-9.706-9.367
TTM-19.0735Y-14.726-4.347
5Y-14.72610Y-13.354-1.372
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-36.647-3.219-33.428
MRQ-19.073-2.705-16.368
TTM-19.073-3.666-15.407
YOY-9.706-4.403-5.303
3Y-13.568-5.059-8.509
5Y-14.726-8.477-6.249
10Y-13.354-9.291-4.063
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Oryzon is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.25 means the investor is paying €1.25Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Oryzon Genomics SA:

  • The EOD is 2.395. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.247. Based on the equity, the company is underpriced. +1
  • The TTM is 1.247. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.395MRQ1.247+1.149
MRQ1.247TTM1.2470.000
TTM1.247YOY1.790-0.543
TTM1.2475Y2.439-1.192
5Y2.43910Y4.944-2.505
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.3951.952+0.443
MRQ1.2471.842-0.595
TTM1.2472.112-0.865
YOY1.7902.439-0.649
3Y1.8952.494-0.599
5Y2.4393.655-1.216
10Y4.9444.311+0.633
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-12-312021-12-312022-12-312023-12-312024-12-31
Income Tax Expense  -1,379-1,114-2,493168-2,325-426-2,7514,6571,906



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets108,716
Total Liabilities21,674
Total Stockholder Equity87,042
 As reported
Total Liabilities 21,674
Total Stockholder Equity+ 87,042
Total Assets = 108,716

Assets

Total Assets108,716
Total Current Assets8,748
Long-term Assets99,969
Total Current Assets
Cash And Cash Equivalents 5,619
Net Receivables 730
Other Current Assets 3,126
Total Current Assets  (as reported)8,748
Total Current Assets  (calculated)9,475
+/- 727
Long-term Assets
Property Plant Equipment 356
Intangible Assets 97,096
Long-term Assets Other 2,517
Long-term Assets  (as reported)99,969
Long-term Assets  (calculated)99,969
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities11,739
Long-term Liabilities9,935
Total Stockholder Equity87,042
Total Current Liabilities
Short-term Debt 8,759
Short Long Term Debt 7,924
Accounts payable 2,126
Other Current Liabilities 854
Total Current Liabilities  (as reported)11,739
Total Current Liabilities  (calculated)19,663
+/- 7,924
Long-term Liabilities
Long term Debt 3,222
Capital Lease Obligations 57
Long-term Liabilities  (as reported)9,935
Long-term Liabilities  (calculated)3,279
+/- 6,656
Total Stockholder Equity
Common Stock3,289
Retained Earnings -19,289
Accumulated Other Comprehensive Income 4,358
Other Stockholders Equity 98,685
Total Stockholder Equity (as reported)87,042
Total Stockholder Equity (calculated)87,042
+/- 0
Other
Capital Stock3,289
Cash and Short Term Investments 5,619
Common Stock Shares Outstanding 64,371
Liabilities and Stockholders Equity 108,716
Net Debt 10,595
Net Invested Capital 98,189
Net Working Capital -2,991
Property Plant and Equipment Gross 2,696
Short Long Term Debt Total 16,213



6.3. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
> Total Assets 
29,210
28,779
28,763
26,058
40,731
49,744
61,044
67,451
80,095
94,107
95,384
103,700
106,900
108,716
108,716106,900103,70095,38494,10780,09567,45161,04449,74440,73126,05828,76328,77929,210
   > Total Current Assets 
0
0
2,851
9,999
22,681
28,475
36,130
35,664
142
42,377
32,606
25,165
14,276
8,748
8,74814,27625,16532,60642,37714235,66436,13028,47522,6819,9992,85100
       Cash And Cash Equivalents 
2,684
2,302
2,033
3,633
19,467
22,028
34,950
34,320
35,111
39,605
28,725
21,317
12,257
5,619
5,61912,25721,31728,72539,60535,11134,32034,95022,02819,4673,6332,0332,3022,684
       Short-term Investments 
2,310
506
142
5,642
2,260
5,242
213
142
142
0
0
0
0
0
000001421422135,2422,2605,6421425062,310
       Net Receivables 
2,322
935
674
6,357
946
1,190
951
1,068
2,194
2,456
3,777
747
1,366
730
7301,3667473,7772,4562,1941,0689511,1909466,3576749352,322
       Inventory 
13
19
2
9
4
8
7
135
289
317
104
10
6
3
3610104317289135784921913
   > Long-term Assets 
0
0
0
0
0
21,269
24,914
31,786
-101
51,729
62,778
78,535
92,624
99,969
99,96992,62478,53562,77851,729-10131,78624,91421,26900000
       Property Plant Equipment 
1,713
1,485
1,159
981
854
696
638
665
707
644
682
611
481
356
3564816116826447076656386968549811,1591,4851,713
       Long Term Investments 
0
0
845
506
344
41
41
41
41
0
0
0
0
0
000004141414134450684500
       Intangible Assets 
248
191
127
32
19
18,810
22,458
29,330
39,938
49,216
60,254
75,843
381
97,096
97,09638175,84360,25449,21639,93829,33022,45818,8101932127191248
       Long-term Assets Other 
0
0
0
0
0
21,269
0
-665
101
66
29
31
89,540
2,517
2,51789,540312966101-665021,26900000
> Total Liabilities 
12,453
12,352
14,035
12,165
13,138
27,015
26,612
22,325
79
18,176
24,122
31,128
25,125
21,674
21,67425,12531,12824,12218,1767922,32526,61227,01513,13812,16514,03512,35212,453
   > Total Current Liabilities 
2,296
2,343
2,724
3,969
5,297
7,597
8,696
10,441
79
7,693
8,672
18,732
16,414
11,739
11,73916,41418,7328,6727,6937910,4418,6967,5975,2973,9692,7242,3432,296
       Short-term Debt 
0
0
11,219
2,670
2,895
4,250
6,385
7,431
5,696
3,791
3,424
10,380
11,939
8,759
8,75911,93910,3803,4243,7915,6967,4316,3854,2502,8952,67011,21900
       Short Long Term Debt 
0
0
11,219
2,670
2,895
4,250
6,385
7,431
5,696
3,791
3,424
10,360
10,215
7,924
7,92410,21510,3603,4243,7915,6967,4316,3854,2502,8952,67011,21900
       Accounts payable 
760
578
454
1,010
1,614
1,603
820
1,607
3,263
2,005
2,910
5,065
3,415
2,126
2,1263,4155,0652,9102,0053,2631,6078201,6031,6141,010454578760
       Other Current Liabilities 
234
246
168
288
445
165
182
188
-8,879
1,679
2,126
3,078
856
854
8548563,0782,1261,679-8,879188182165445288168246234
   > Long-term Liabilities 
0
0
0
0
0
19,419
17,915
11,884
8,420
10,483
15,451
12,396
8,711
9,935
9,9358,71112,39615,45110,4838,42011,88417,91519,41900000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
5,302
10,347
7,061
0
0
007,06110,3475,302000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000
       Deferred Long Term Liability 
0
0
21,421
12,896
15,169
18,786
22,429
29,210
39,488
49,009
59,624
75,322
0
0
0075,32259,62449,00939,48829,21022,42918,78615,16912,89621,42100
> Total Stockholder Equity
16,757
16,427
14,728
13,893
27,593
22,729
34,432
45,125
61,129
75,931
71,262
72,572
81,775
87,042
87,04281,77572,57271,26275,93161,12945,12534,43222,72927,59313,89314,72816,42716,757
   Common Stock
236
236
236
236
1,139
1,423
1,708
1,956
2,289
2,653
2,653
2,778
3,056
3,289
3,2893,0562,7782,6532,6532,2891,9561,7081,4231,139236236236236
   Retained Earnings Total Equity00000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
2,506
4,358
4,3582,506000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
73,961
73,961
79,687
0
0
0079,68773,96173,961000000000
   Treasury Stock0000000-1,540-1,791-1,711-1,711-215-215-215
   Other Stockholders Equity 
0
0
4,436
3,944
2,103
2,767
1,196
66
79,532
73,267
73,267
79,067
94,390
98,685
98,68594,39079,06773,26773,26779,532661,1962,7672,1033,9444,43600



6.4. Balance Sheets

Currency in EUR. All numbers in thousands.




6.5. Cash Flows

Currency in EUR. All numbers in thousands.




6.6. Income Statements

Currency in EUR. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue7,359
Cost of Revenue-302
Gross Profit7,0577,057
 
Operating Income (+$)
Gross Profit7,057
Operating Expense-11,480
Operating Income-4,423-4,423
 
Operating Expense (+$)
Research Development-
Selling General Administrative-
Selling And Marketing Expenses-
Operating Expense11,4800
 
Net Interest Income (+$)
Interest Income116
Interest Expense-1,227
Other Finance Cost-0
Net Interest Income-1,111
 
Pretax Income (+$)
Operating Income-4,423
Net Interest Income-1,111
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-5,571-3,275
EBIT - interestExpense = -5,808
-1,759
-2,438
Interest Expense1,227
Earnings Before Interest and Taxes (EBIT)-4,582-4,344
Earnings Before Interest and Taxes (EBITDA)-4,434
 
After tax Income (+$)
Income Before Tax-5,571
Tax Provision--1,906
Net Income From Continuing Ops-3,665-3,665
Net Income-3,665
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses11,782
Total Other Income/Expenses Net-1,1481,111
 

Technical Analysis of Oryzon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Oryzon. The general trend of Oryzon is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Oryzon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Oryzon Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Oryzon Genomics SA.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 2.715 < 2.79 < 2.96.

The bearish price targets are: 2.59 > 2.575 > 2.51.

Know someone who trades $ORY? Share this with them.πŸ‘‡

Oryzon Genomics SA Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Oryzon Genomics SA. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Oryzon Genomics SA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Oryzon Genomics SA. The current macd is -0.02494824.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Oryzon price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Oryzon. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Oryzon price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Oryzon Genomics SA Daily Moving Average Convergence/Divergence (MACD) ChartOryzon Genomics SA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Oryzon Genomics SA. The current adx is 9.65392325.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Oryzon shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Oryzon Genomics SA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Oryzon Genomics SA. The current sar is 2.89231694.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Oryzon Genomics SA Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Oryzon Genomics SA. The current rsi is 46.06. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Oryzon Genomics SA Daily Relative Strength Index (RSI) ChartOryzon Genomics SA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Oryzon Genomics SA. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Oryzon price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Oryzon Genomics SA Daily Stochastic Oscillator ChartOryzon Genomics SA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Oryzon Genomics SA. The current cci is -51.64908756.

Oryzon Genomics SA Daily Commodity Channel Index (CCI) ChartOryzon Genomics SA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Oryzon Genomics SA. The current cmo is -10.38258325.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Oryzon Genomics SA Daily Chande Momentum Oscillator (CMO) ChartOryzon Genomics SA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Oryzon Genomics SA. The current willr is -66.66666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Oryzon is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Oryzon Genomics SA Daily Williams %R ChartOryzon Genomics SA Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Oryzon Genomics SA.

Oryzon Genomics SA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Oryzon Genomics SA. The current atr is 0.09453317.

Oryzon Genomics SA Daily Average True Range (ATR) ChartOryzon Genomics SA Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Oryzon Genomics SA. The current obv is 7,312,298.

Oryzon Genomics SA Daily On-Balance Volume (OBV) ChartOryzon Genomics SA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Oryzon Genomics SA. The current mfi is 33.54.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Oryzon Genomics SA Daily Money Flow Index (MFI) ChartOryzon Genomics SA Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Oryzon Genomics SA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-17STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-20ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-03-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Oryzon Genomics SA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Oryzon Genomics SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.061
Ma 20Greater thanMa 502.745
Ma 50Greater thanMa 1002.727
Ma 100Greater thanMa 2002.766
OpenGreater thanClose2.685
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Oryzon with someone you think should read this too:
  • Are you bullish or bearish on Oryzon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Oryzon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Oryzon Genomics SA

I send you an email if I find something interesting about Oryzon Genomics SA.


Comments

How you think about this?

Leave a comment

Stay informed about Oryzon Genomics SA.

Receive notifications about Oryzon Genomics SA in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.